Research ArticleGASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL
Pharmacological Characterization of Olodaterol, a Novel Inhaled β2-Adrenoceptor Agonist Exerting a 24-Hour-Long Duration of Action in Preclinical Models
T. Bouyssou, P. Casarosa, E. Naline, S. Pestel, I. Konetzki, P. Devillier and A. Schnapp
Journal of Pharmacology and Experimental Therapeutics July 2010, 334 (1) 53-62; DOI: https://doi.org/10.1124/jpet.110.167007
T. Bouyssou
Boehringer Ingelheim Pharma GmbH & Co. Biberach, Germany (T.B., P.C., S.P., I.K., A.S.); and Unité Propre de Recherche et de l'Enseignement Supérieur EA220, Hôpital Foch, Université Versailles, Saint Quentin, Suresnes, France (E.N., P.D.)
P. Casarosa
Boehringer Ingelheim Pharma GmbH & Co. Biberach, Germany (T.B., P.C., S.P., I.K., A.S.); and Unité Propre de Recherche et de l'Enseignement Supérieur EA220, Hôpital Foch, Université Versailles, Saint Quentin, Suresnes, France (E.N., P.D.)
E. Naline
Boehringer Ingelheim Pharma GmbH & Co. Biberach, Germany (T.B., P.C., S.P., I.K., A.S.); and Unité Propre de Recherche et de l'Enseignement Supérieur EA220, Hôpital Foch, Université Versailles, Saint Quentin, Suresnes, France (E.N., P.D.)
S. Pestel
Boehringer Ingelheim Pharma GmbH & Co. Biberach, Germany (T.B., P.C., S.P., I.K., A.S.); and Unité Propre de Recherche et de l'Enseignement Supérieur EA220, Hôpital Foch, Université Versailles, Saint Quentin, Suresnes, France (E.N., P.D.)
I. Konetzki
Boehringer Ingelheim Pharma GmbH & Co. Biberach, Germany (T.B., P.C., S.P., I.K., A.S.); and Unité Propre de Recherche et de l'Enseignement Supérieur EA220, Hôpital Foch, Université Versailles, Saint Quentin, Suresnes, France (E.N., P.D.)
P. Devillier
Boehringer Ingelheim Pharma GmbH & Co. Biberach, Germany (T.B., P.C., S.P., I.K., A.S.); and Unité Propre de Recherche et de l'Enseignement Supérieur EA220, Hôpital Foch, Université Versailles, Saint Quentin, Suresnes, France (E.N., P.D.)
A. Schnapp
Boehringer Ingelheim Pharma GmbH & Co. Biberach, Germany (T.B., P.C., S.P., I.K., A.S.); and Unité Propre de Recherche et de l'Enseignement Supérieur EA220, Hôpital Foch, Université Versailles, Saint Quentin, Suresnes, France (E.N., P.D.)
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleGASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL
Pharmacological Characterization of Olodaterol, a Novel Inhaled β2-Adrenoceptor Agonist Exerting a 24-Hour-Long Duration of Action in Preclinical Models
T. Bouyssou, P. Casarosa, E. Naline, S. Pestel, I. Konetzki, P. Devillier and A. Schnapp
Journal of Pharmacology and Experimental Therapeutics July 1, 2010, 334 (1) 53-62; DOI: https://doi.org/10.1124/jpet.110.167007
Research ArticleGASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL
Pharmacological Characterization of Olodaterol, a Novel Inhaled β2-Adrenoceptor Agonist Exerting a 24-Hour-Long Duration of Action in Preclinical Models
T. Bouyssou, P. Casarosa, E. Naline, S. Pestel, I. Konetzki, P. Devillier and A. Schnapp
Journal of Pharmacology and Experimental Therapeutics July 1, 2010, 334 (1) 53-62; DOI: https://doi.org/10.1124/jpet.110.167007
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement